The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

THEY have taken the nation’s waistlines by storm, helping thousands shed pounds and trim inches. So-called fat jabs have been dubbed a “miracle” – helping turn the tide on ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.

A WOMAN has shared the brutally honest truth about what happened when she was forced to ”go cold turkey” from Mounjaro.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

“The number one reason patients stop taking Wegovy or Mounjaro is gastrointestinal distress,” says Curran. “The nausea, vomiting, diarrhea, and constipation can be really intense, especially if a dose ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in ...